Circle Pharma Expands Leadership Team Amid Oncology Pipeline Growth

As it works to expand its MXMO macrocycle discovery platform and oncology pipeline, Circle Pharma, a clinical-stage biopharmaceutical company committed to finding and creating cell-permeable macrocycles as a new class of treatments, announced today the addition of two executive members to key positions. Constantine Kreatsoulas, Ph.D., has been elevated to Senior Vice President and Head of Discovery Technology Sciences, replacing Marie Evangelista, Ph.D., as the head of cancer biology. These hires complement Circle's investments in its pipeline of macrocycle treatments, which includes CID-078, the main program that is presently the subject of a Phase 1 clinical study for solid tumours.

With over eighteen years of expertise in small molecule drug discovery and translational oncology, Dr. Evangelista has guided successful programs from early discovery to clinical development. She worked at Genentech for fifteen years before joining Circle, and during that time, her leadership helped the company's KRAS-targeting initiatives advance. Dr. Evangelista had executive positions at Frontier Medicines and, most recently, Recursion after leaving Genentech. Dr. Evangelista graduated from Queen's University in Ontario, Canada, with a Ph.D. in cell and molecular biology.

Dr. Evangelista remarked, "I'm thrilled to join Circle at this critical juncture, where its innovative macrocycle platform is translating into clinical progress." "I'm excited to contribute to the creation of treatments that will change patients' lives."

Since joining Circle Pharma in 2021, Dr. Kreatsoulas has been instrumental in driving the company's progress. He has supervised the creation of the MXMO platform and helped push CID-078 closer to the clinic. He was a leader at Bristol-Myers Squibb, Merck & Co., and GlaxoSmithKline (GSK) before to joining Circle Pharma. He specialised in computational toxicology, machine learning, and molecular design. He graduated with a master's degree in regulatory affairs and quality assurance from Temple University and a doctorate in chemistry from Princeton University.

As Dr. Kreatsoulas put it, "being a part of Circle's evolution to a clinical-stage company has been incredibly rewarding." "As we continue to develop our revolutionary macrocycle technologies, I am thrilled to take on the role of Head of Discovery Technology Sciences."